RxDoctor Payments Data

Victoria Greblya, MD

Internal Medicine · Westminster, CANPI 1790720969

Payments from drug & device makers

$2,574in general payments, 2019–2025

Across 113 payments — averaging $22.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$419
  • Madrigal Pharmaceuticals$385
  • Astellas Pharma US Inc$333
  • Lilly USA, LLC$249
  • Novartis$193
  • Novo Nordisk$165
  • plus $831 from 19 others

What the payments were for

  • Food & beverage$2,47496%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,574 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$56,899
Medicare patients
173
Services billed
679

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$97,975
EliquisApixaban66$78,813
JardianceEmpagliflozin48$65,340
ProliaDenosumab25$41,187
TrulicityDulaglutide26$31,298
XareltoRivaroxaban19$30,599
TradjentaLinagliptin27$29,542
LinzessLinaclotide23$25,799
BelsomraSuvorexant18$15,982
MounjaroTirzepatide12$15,429
NexletolBempedoic Acid13$15,022
JanumetSitagliptin Phos/Metformin Hcl15$13,526
JanuviaSitagliptin Phosphate12$12,657
VascepaIcosapent Ethyl12$12,255
Tresiba Flextouch U-100Insulin Degludec12$10,971

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$165$97,97569 claims
PfizerEliquis$51$78,81366 claims
MerckBelsomra, Janumet, Januvia, Janumet Xr$70$53,03561 claims
Lilly USA, LLCTrulicity, Mounjaro$249$46,72738 claims
AmgenProlia$419$41,18725 claims
Johnson & JohnsonXarelto$53$30,59919 claims
AbbVieLinzess, Synthroid$76$28,52055 claims
Esperion Therapeutics, Inc.Nexletol$40$15,02213 claims
GSKTrelegy Ellipta$32$7,58612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Westminster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →